Durvalumab (intravenous route)

Imfinzi

Durvalumab injection is used in combination with platinum-containing chemotherapy before surgery and then used alone after surgery in patients with non-small cell lung cancer (NSCLC) which can be removed by surgery and do not have an abnormal EGFR or ALK gene. It is also used alone to treat NSCLC that has not spread and cannot be removed by surgery in patients who have received other cancer medicines (eg, platinum) and radiation treatment for their NSCLC. It is also used in combination with tremelimumab-actl to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body in patients whose tumors do not have an abnormal EGFR or ALK gene. This medicine is also used in combination with etoposide and either carboplatin or cisplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Durvalumab injection is also used in combination with other cancer medicines (eg, gemcitabine, cisplatin) to treat biliary tract cancer (BTC) that has spread to nearby tissues or to other parts of the body. Durvalumab injection is also used in combination with tremelimumab-actl to treat liver cancer that cannot be removed by surgery (unresectable hepatocellular carcinoma or uHCC). Durvalumab injection is also used alone or in combination with other cancer medicines (eg, carboplatin and paclitaxel) to treat mismatch repair deficient (dMMR) advanced endometrial cancer (cancer of the lining of the uterus or womb) that has spread or has come back. This medicine is to be given only by or under the supervision of your doctor. This product is available in the following dosage forms:

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered: Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully. Appropriate studies have not been performed on the relationship of age to the effects of durvalumab injection in the pediatric population. Safety and efficacy have not been established. Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of durvalumab injection in the elderly. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine. Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco. The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially: